Heart failure is a complex syndrome and affects over 5.1 Million Americans today with approximately 500,000 new heart failure cases each year. Heart failure is the leading cause of emergency room visits, hospitalizations, and death for Americans today. Although, there have been significant advances in heart failure diagnosis, management, and treatment there is still a need for new tools to help optimize the management of this healthcare burden. Recently, novel biomarkers have emerged as additional tools to aid in prognosis and management of heart failure. During today's webcast, we will learn about a new and emerging biomarker called galectin-3 and how it can be used as a management tool for heart failure patients in the US.
Learning Objectives: • Understand what is galectin-3 • Learn about pathophysiology of cardiac fibrosis and the role of galectin-3 • Comprehend how galectin-3 can used as a management tool for heart failure patients
Who Should Attend: • Laboratorians • Heart failure nurses • Heart failure specialists • Cardiologists • Emergency Physicians